Current status and prospective of neoadjuvant immune checkpoint inhibitors for resectable non-small cell lung cancer
- VernacularTitle:免疫检查点抑制剂新辅助治疗可切除非小细胞肺癌现状与展望
- Author:
Rusi ZHANG
1
,
2
,
3
;
Lanjun ZHANG
1
,
2
Author Information
1. 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510000, P.R.China
2. 2. Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510000, P.R.China
3. 3. Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510000, P.R.China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
neoadjuvant therapy;
immune checkpoint inhibitor;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2020;27(11):1348-1352
- CountryChina
- Language:Chinese
-
Abstract:
Surgery remains as the primary definitive therapy for resectable non-small cell lung cancer (NSCLC) currently. However, quite a few NSCLC patients, especially in the later stage, suffered tumor recurrence after resection. Safer and more effective perioperative treatment is urgently needed to reduce the recurrence risk after NSCLC surgery. Immune checkpoint inhibitors can effectively prevent tumor immune evasion and have been shown to be a feasible, safe and effective neoadjuvant therapy for resectable NSCLC. Nevertheless, certain crucial problems, including the final effect on NSCLC recurrence, the selection of beneficial group and optimal treatment protocol are yet unsolved. Fortunately, several phase Ⅲ randomized controlled trials are ongoing to answer these questions and will hopefully provide stronger evidence.
